NCT05187819Recruiting
Blood-based Biomarkers for Diagnosis of Alzheimer's
Accuracy of Blood-based Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice
Source: ClinicalTrials.gov · Last updated 28 Sept 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD. This project will assess the predictive value of these tests in a general practice population. The hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 24 Dec 2021
- Start date
- 1 Jun 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Helse Stavanger HF
- Diseases
- Alzheimer disease
- NCT number
- NCT05187819
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 1 Jun 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment.
Other
- Lack of capacity for consent as judged by the GP.
- Patients not wanting to be referred to the memory outpatient clinic.
Who the study is looking for
- Participants suspected by their GP to have possible dementia, based on history, clinical examination and/or cognitive screening
Age in the registry: 40 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stavanger University Hospital Coordinator of this site? Confirm its status | Stavanger | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.